Literature DB >> 10678602

Botulinum toxin injection of spastic finger flexors in hemiplegic patients.

A A Rodriquez1, M McGinn, R Chappell.   

Abstract

OBJECTIVE: To assess the outcomes of botulinum toxin injection of spastic finger flexors followed by intensive training of finger extensors.
DESIGN: Fourteen subjects with chronic hemiplegia spasticity of the upper limb had electromyographic-guided botulinum toxin injection into the long finger flexors. All patients presented with minimal active finger extension with the wrist flexed, sustained clonus of the finger flexors, functional proximal arm function, and absence of fixed contracture. Cadaver dissections directed selection of two injection sites: the flexor digitorum sublimis and the flexor digitorum profundus. Fifty mouse units of botulinum toxin were injected into each muscle. After injection, the subjects were instructed in a home program of stretching the long finger flexors, upper limb weight bearing with a weight-bearing splint, and exercise to improve finger extension control.
RESULTS: Compared with preinjection measures, assessment the first week after the initial injection showed significantly reduced tone, reduced clonus, and greater active finger extension with the wrist in the neutral position. Four months later, the Ashworth scale increased to preinjection levels in the six subjects with repeated injections but was again decreased postinjection. Active finger extension with the wrist in the neutral position and clonus showed a statistically nonsignificant trend toward cumulative improvement after the second injection.
CONCLUSION: The greatest change in finger extension and spasticity reduction occurred after the first injection. Continued significant improvement in finger extension was not observed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678602     DOI: 10.1097/00002060-200001000-00010

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  7 in total

1.  Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.

Authors:  H P Francis; D T Wade; L Turner-Stokes; R S Kingswell; C S Dott; E A Coxon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 2.  Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.

Authors:  Geoffrey Sheean
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Botulinum toxin use as an adjunctive modality in a patient with multiple flexor tendon ruptures.

Authors:  Wade D Kubat; Mark Rekant
Journal:  Hand (N Y)       Date:  2008-03-14

4.  Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?

Authors:  Dong-wook Rha; Eun Joo Yang; Ho Ik Chung; Hyoung Bin Kim; Chang-il Park; Eun Sook Park
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

5.  Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management.

Authors:  Lynne Turner-Stokes; Klemens Fheodoroff; Jorge Jacinto; Pascal Maisonobe
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

6.  Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice.

Authors:  Lynne Turner-Stokes; Klemens Fheodoroff; Jorge Jacinto; Pascal Maisonobe; Benjamin Zakine
Journal:  BMJ Open       Date:  2013-03-18       Impact factor: 2.692

7.  Botulinum Toxin Injections and Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke.

Authors:  Jong-Min Lee; Jean-Michel Gracies; Si-Bog Park; Kyu Hoon Lee; Ji Yeong Lee; Joon-Ho Shin
Journal:  Toxins (Basel)       Date:  2018-10-25       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.